Quinazoline derivatives

Abstract

The invention relates to the use of compounds of the formula I: wherein: ring C is a 5-6 membered heterocyclic moiety; Z is —O—, —S—, or —CH—; Ris hydrogen, Calkyl, Calkoxymethyl, di(C)alkoxy)methyl, Calkanoyl, trifluoromethyl, cyano, amino, Calkenyl, Calkynyl, carboxy, Ccycloalkyl, C-cycloalkylCalkyl, or an optionally substituted group selected from phenyl, benzyl, phenylCalkyl and a 5-6 membered heterocyclic group; n is an integer from 0 to 5; m is an integer from 0 to 3; Rrepresents hydrogen, hydroxy, halgeno, cyano, nitro, trifluoromethyl, Calkyl, Calkoxy, Calkylsulphanyl, —NRR(wherein Rand R, which may be the same or different, each represents hydrogen or Calkyl), or RX— (wherein Xrepresents a direct bond, —CH—, or a heteroatom linker group and Ris an alkyl, alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, which alkyl, alkenyl or alkynyl chain may have a heteroatom linker group, or Ris an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.